Oryon Cell Therapies Raises USD 42m as It Exits Stealth With Parkinson's Cell Therapy Program

Oryon Cell Therapies, a clinical-stage company headquartered in Belmont, Massachusetts, has emerged from stealth with USD 42 million in total financing directed toward its autologous neuron replacement therapy for Parkinson's disease and other neurodegenerative disorders. The latest tranche, a USD 21 million addition to the company's Series A round, brings total funding from equity and grants to the USD 42 million figure, the company said.

Investors in the round included Neuro.VC, Byers Capital, and undisclosed additional participants. No lead investor was specified. Oryon said the financing will support completion of an ongoing Phase 1b/2a clinical trial of its lead neuron replacement therapy, along with manufacturing scale-up and regulatory engagement needed to advance toward a Phase 3 trial.

Oryon's lead and sole disclosed program is an autologous iPSC-derived dopaminergic neuron replacement therapy for Parkinson's disease. The approach takes a patient's own blood cells, reprograms them into induced pluripotent stem cells, and differentiates those cells into dopaminergic neurons using proprietary methods. The resulting neurons are implanted directly into the putamen, the brain region most associated with Parkinson's motor symptoms. Because the cells are derived from the patient, chronic immunosuppression is not required, a distinction from allogeneic cell therapy approaches that rely on donor-derived material.

The Phase 1b/2a trial is being conducted at Brigham & Women's Hospital/Harvard Medical School. Early clinical data from the study, presented at the AD/PD 2026 International Conference on Alzheimer's and Parkinson's Diseases, showed motor improvements in treated patients alongside neuroimaging evidence of restored dopaminergic signaling, the company said. No additional pipeline candidates or indications beyond Parkinson's disease have been disclosed, though Oryon has stated a broader interest in neurodegenerative disorders.

The company's underlying science originated from research conducted over three decades at Harvard University and Mass General Brigham. Ole Isacson, founding director of the Neuroregeneration Research Institute at McLean Hospital/Harvard Medical School, co-founded Oryon in 2020 alongside Nikola Kojic. Penelope Hallett, co-director of the same institute, presented the Phase 1b/2a data at the AD/PD conference.

Concurrent with the financing, Oryon appointed Ron Cohen as chief executive officer. Cohen founded Acorda Therapeutics, a public company that developed and commercialized therapies for neurological disorders including Parkinson's disease and multiple sclerosis, and served as its president and CEO until Merz Therapeutics acquired Acorda's commercial portfolio in 2024. Prior to Acorda, Cohen was a principal in the startup of Advanced Tissue Sciences, a company focused on human organ tissue growth for transplantation. He holds an M.D. from Columbia College of Physicians & Surgeons and a B.A. from Princeton University. No previous funding rounds beyond the cumulative USD 42 million Series A have been disclosed, and no licensing or partnership deals with other pharmaceutical or biotechnology companies have been reported.

---

Spot something wrong? Report an issue with this article